Significant accounting policies
Significant Accounting Policies [Text Block]
Range [Domain]
Statistical Measurement [Domain]
Award Timing Predetermined
Award Timing Predetermined [Flag]
Related Party Transaction [Axis]
Related Party Transaction [Axis]
Entity File Number
Entity File Number
Additional Paid-In Capital
Additional Paid-in Capital [Member]
AB-101-001 Phase 1a/1b clinical trial expense
AB-101-001 Phase 1a/b clinical trial expense
AB-101-001 Phase 1a/b clinical trial expense
Tabular List, Table
Tabular List [Table Text Block]
Recent accounting pronouncements
New Accounting Pronouncements, Policy [Policy Text Block]
Interest income
Interest Income, Interest-Earning Asset
Deferred license revenue, non-current
Deferred Revenue, Noncurrent
Type of Restructuring [Domain]
Type of Restructuring [Domain]
Revenue from collaborations and licenses
License [Member]
Gross Unrealized Loss
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Trading Arrangements, by Individual
Trading Arrangements, by Individual [Table]
Basic (in USD per share)
Earnings Per Share, Basic
Adjustment to Compensation:
Adjustment to Compensation [Axis]
Related Party Transaction
Related Party Transactions Disclosure [Text Block]
Named Executive Officers, Footnote
Named Executive Officers, Footnote [Text Block]
Accounts payable and accrued liabilities
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Liabilities
Liabilities, Fair Value Disclosure [Abstract]
US treasury bills
US Treasury Bill Securities [Member]
Summary of collaborations
Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]
Schedule of Stock by Class [Table]
Stock, Class of Stock [Table]
Restructuring And Workforce Reduction
Restructuring And Workforce Reduction [Member]
Restructuring And Workforce Reduction
Effective annual interest rate on royalty liability
Effective Annual Interest Rate Of Royalty Liability
Effective Annual Interest Rate Of Royalty Liability
Schedule of Segment Reporting Information, by Segment
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Issuance of common shares upon vesting of RSUs
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures
Issuance of common shares pursuant to ESPP (in shares)
Stock Issued During Period, Shares, Employee Stock Purchase Plans
Revenue, remaining performance obligation, amount
Revenue, Remaining Performance Obligation, Amount
Short Term Marketable Securities
Investments in marketable securities, current [Member]
Investments in marketable securities, current
Adjustment to Compensation, Amount
Adjustment to Compensation Amount
Principles of consolidation
Consolidation, Policy [Policy Text Block]
Stock-based compensation expense
Share-Based Payment Arrangement, Noncash Expense
Employee Stock Option
Share-Based Payment Arrangement, Option [Member]
Award Timing MNPI Disclosure
Award Timing MNPI Disclosure [Text Block]
Moderna And Pfizer/BioNTech
Moderna Therapeutics, Inc And Pfizer Inc And BioNTech SE [Member]
Moderna Therapeutics, Inc And Pfizer Inc And BioNTech SE
Income taxes paid
Income Taxes Paid
Antidilutive Securities [Axis]
Antidilutive Securities [Axis]
Total stockholders’ equity
Beginning balance
Ending balance
Equity, Attributable to Parent
Measurement Frequency [Axis]
Measurement Frequency [Axis]
Insider Trading Policies and Procedures [Line Items]
Allocated share-based compensation expense
Share-Based Payment Arrangement, Expense
Current assets:
Assets, Current [Abstract]
Total liabilities and stockholders’ equity
Liabilities and Equity
Recurring
Fair Value, Recurring [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Liabilities and stockholders’ equity
Liabilities and Equity [Abstract]
Cover [Abstract]
Cash and cash equivalents
Cash and Cash Equivalents, Fair Value Disclosure
Issuance of common shares pursuant to the Open Market Sale Agreement
Stock Issued During Period, Value, New Issues, Open Market Sale Agreement
Stock Issued During Period, Value, New Issues, Open Market Sale Agreement
Maximum
Maximum [Member]
General and administrative
General and Administrative Expense [Member]
Premium on closing stock price ($ paid)
Premium on closing stock price ($ paid)
Premium on closing stock price ($ paid)
Schedule of Equity Method Investments [Table]
Equity Method Investment [Table]
Accounting Policies [Abstract]
One-Time Upfront Cash Payment
One-Time Upfront Cash Payment [Member]
One-Time Upfront Cash Payment
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Total Compensation Amount
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Adjustment to Non-PEO NEO Compensation Footnote
Adjustment to Non-PEO NEO Compensation Footnote [Text Block]
Pay vs Performance Disclosure [Line Items]
Royalty interest sold, annual revenue threshold of highest tier
Annual Revenue Threshold
Annual Revenue Threshold
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Non-Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated [Flag]
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc [Member]
Alnylam Pharmaceuticals, Inc
Entity Shell Company
Entity Shell Company
Research and development accruals
Accrued Research And Development
Research and development accruals
Proceeds from sale of property and equipment
Proceeds from Sale of Property, Plant, and Equipment
Change in deferred license revenue
Increase (Decrease) in Deferred Revenue
Statement of Stockholders' Equity [Abstract]
Statement of Cash Flows [Abstract]
Company Selected Measure Amount
Company Selected Measure Amount
Award Timing MNPI Considered
Award Timing MNPI Considered [Flag]
Comprehensive income (loss)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Liability related to sale of future royalties
Net liability related to sale of future royalties - beginning balance
Net liability related to sale of future royalties - ending balance
Liability Related To Sale Of Future Royalties, Noncurrent
Liability Related To Sale Of Future Royalties, Noncurrent
Name
Measure Name
Schedule of stock based compensation expense
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Lease liability, current
Operating Lease, Liability, Current
Class of Stock [Line Items]
Class of Stock [Line Items]
Stock Options And Restricted Stock Units
Stock Options And Restricted Stock Units [Member]
Stock Options And Restricted Stock Units
Document Fiscal Period Focus
Document Fiscal Period Focus
Contingencies and Commitments [Table]
Contingencies and Commitments [Table]
Award Timing Method
Award Timing Method [Text Block]
Litigation Case [Domain]
Litigation Case [Domain]
Award Type
Award Type [Axis]
Sale Agreement
Sale Agreement [Member]
Sale Agreement
Long-term debt
Long-Term Debt
Legal Entity [Axis]
Legal Entity [Axis]
Total assets
Assets
Investment, Name [Domain]
Investment, Name [Domain]
Trading Symbol
Trading Symbol
Number of royalty entitlements
Royalty Entitlements
Royalty Entitlements
Non-cash royalty revenue
Non-Cash Royalty [Member]
Non-Cash Royalty
Non-cash royalty revenue
Liability From Sale Of Future Royalties, Non Cash Royalty Income
Liability From Sale Of Future Royalties, Non Cash Royalty Income
Sub-licensing revenue percentage
Sub-licensing revenue Percentage
Sub-licensing revenue Percentage
Entity Address, City or Town
Entity Address, City or Town
OPERATING ACTIVITIES
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]
Marketable Securities [Line Items]
Marketable Securities [Line Items]
Adjustments and reconciling items
Segment Reporting, Other Segment Item, Amount
Contingency, Pending Claims, Number
Contingency, Pending Claims, Number
Contingency, Pending Claims, Number
Effect of foreign exchange rate changes on cash and cash equivalents
Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Issuance of common shares pursuant to the Open Market Sale Agreement (in shares)
Stock Issued During Period, Shares, New Issues, Open Market Sale Agreement
Stock Issued During Period, Shares, New Issues, Open Market Sale Agreement
Non-PEO NEO Average Compensation Actually Paid Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Income Statement Location [Domain]
Statement of Income Location, Balance [Domain]
Cash severance
Severance Costs
Compensation Actually Paid vs. Other Measure
Compensation Actually Paid vs. Other Measure [Text Block]
Assets
Assets, Fair Value Disclosure [Abstract]
Entity Emerging Growth Company
Entity Emerging Growth Company
Restructuring liabilities
Restructuring liabilities
Restructuring Reserve, Current
Impairment of laboratory equipment
Impairment, Long-Lived Asset, Held-for-Use
Reportable Segment
Reportable Segment [Member]
Reportable Segment
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-Sale [Line Items]
Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year
Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]
Level 2
Fair Value, Inputs, Level 2 [Member]
Payroll accruals
Accrued Payroll Current
Accrued Payroll Current
Equity investment
Equity Method Investments
Insider Trading Policies and Procedures Not Adopted
Insider Trading Policies and Procedures Not Adopted [Text Block]
Business Combination [Domain]
Business Combination [Domain]
Common shares, shares outstanding (in shares)
Beginning balance (in shares)
Ending balance (in shares)
Common Stock, Shares, Outstanding
Marketable securities
Marketable Securities [Table Text Block]
Plan Name [Axis]
Plan Name [Axis]
PEO
PEO [Member]
Employee Severance
Employee Severance [Member]
Disposition of investments in marketable securities
Proceeds from Sale, Maturity and Collection of Investments
Interest income
Investment Income, Interest
Future royalty payments
Royalty Payable
Represents the royalty payable.
Net change in operating items:
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]
Issuance of common shares pursuant to ESPP
Stock Issued During Period, Value, Stock Options Exercised
Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year
Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]
Deficit
Retained Earnings [Member]
Prepaid expenses and other current assets
Prepaid Expense and Other Assets, Current
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Restatement Determination Date
Restatement Determination Date
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Income Statement [Abstract]
Sale of Stock [Domain]
Sale of Stock [Domain]
Investments in marketable securities, current
Investments, Fair Value Disclosure
Pension Adjustments Service Cost
Pension Adjustments Service Cost [Member]
Other segment expense
Other segment expense
Other segment expense
Vaccitech
Barinthus [Member]
Barinthus
Product and Service [Domain]
Product and Service [Domain]
Debt Securities, Available-for-Sale [Abstract]
Debt Securities, Available-for-Sale [Abstract]
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV [Axis]
Schedule of changes in fair value of contingent consideration
Business Combination, Contingent Consideration [Table Text Block]
Restatement does not require Recovery
Restatement Does Not Require Recovery [Text Block]
Total
Liabilities, Fair Value Disclosure
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Compensation Actually Paid vs. Company Selected Measure
Compensation Actually Paid vs. Company Selected Measure [Text Block]
Issuance of common shares pursuant to exercise of stock options
Proceeds from Stock Options Exercised
City Area Code
City Area Code
Award Timing, How MNPI Considered
Award Timing, How MNPI Considered [Text Block]
Proceeds from collaborators
Proceeds from Collaborators
All Trading Arrangements
All Trading Arrangements [Member]
Equity Awards Adjustments, Footnote
Equity Awards Adjustments, Footnote [Text Block]
Total Shareholder Return Vs Peer Group
Total Shareholder Return Vs Peer Group [Text Block]
Commitments and Contingencies Disclosure [Abstract]
Schedule of deferred collaborations and contracts revenue
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
INVESTING ACTIVITIES
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]
General and administrative
General and Administrative Expense
Pay vs Performance Disclosure
Pay vs Performance Disclosure [Table]
Net cash used in operating activities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Related Party Transactions [Abstract]
Equity Method Investments and Joint Ventures [Abstract]
Realized gains or losses
Debt Securities, Realized Gain (Loss)
Subsequent Event
Subsequent Event [Member]
Schedule of Equity Method Investments [Line Items]
Schedule of Equity Method Investments [Line Items]
Equity Valuation Assumption Difference, Footnote
Equity Valuation Assumption Difference, Footnote [Text Block]
PEO Total Compensation Amount
PEO Total Compensation Amount
Money market funds
Money Market Funds [Member]
Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]
Research and Development, Contract to Perform for Others [Table]
Equity Components [Axis]
Equity Components [Axis]
Nature of business and future operations
Nature of Operations [Text Block]
Non-Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted [Flag]
Cash
Investments and Cash
Issuance of common shares pursuant to the Open Market Sale Agreement
Proceeds from Issuance of Common Stock, Open Market Sale agreement
Proceeds from Issuance of Common Stock, Open Market Sale agreement
Number of reportable segments
Number of Reportable Segments
Amortized Cost
Debt Securities, Available-for-Sale, Amortized Cost
Noncash modification of equity awards
Other Restructuring Costs
Restructuring Cost and Reserve [Line Items]
Restructuring Cost and Reserve [Line Items]
Other Performance Measure, Amount
Other Performance Measure, Amount
Entity Address, State or Province
Entity Address, State or Province
Operating Lease, Impairment Loss
Operating Lease, Impairment Loss
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Security, Excluded EPS Calculation [Table]
Fair value measurements
Fair Value Measurement, Policy [Policy Text Block]
ONPATTRO
ONPATTRO, global net sales [Member]
ONPATTRO, global net sales
Related and Nonrelated Parties [Domain]
Related and Nonrelated Parties [Domain]
Total current liabilities
Liabilities, Current
Restructuring and related cost, number of positions eliminated, percent
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent
Collaborations and licenses
Collaboration And Contracts [Member]
Collaboration And Contracts [Member]
Litigation Status [Axis]
Litigation Status [Axis]
Individual:
Individual [Axis]
Development and regulatory milestones payment per royalty, maximum
License Agreement Maximum Development And Regulatory Milestone Payments Per Royalty
License Agreement Maximum Development And Regulatory Royalty Payment per Royalty
Research and development
Research and Development Expense [Member]
Entity [Domain]
Entity [Domain]
Accrual of lease-related operating expenses
Other Restructuring [Member]
Net cash provided by investing activities
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table
Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]
Document Fiscal Year Focus
Document Fiscal Year Focus
Basis of presentation
Basis of Accounting, Policy [Policy Text Block]
Right of use asset
Operating Lease, Right-of-Use Asset
Forgone Recovery, Explanation of Impracticability
Forgone Recovery, Explanation of Impracticability [Text Block]
Noncontrolling interest, ownership percentage by noncontrolling owners
Subsidiary, Ownership Percentage, Noncontrolling Owner
Entity Interactive Data Current
Entity Interactive Data Current
Plan Name [Domain]
Plan Name [Domain]
Issuance of common shares pursuant to exercise of options (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Revenue from collaborations and licenses and Deferred Revenue
Revenue from Contract with Customer [Policy Text Block]
US government bonds
US Government Bonds [Member]
US Government Bonds [Member]
Segment Reporting Disclosure
Segment Reporting Disclosure [Text Block]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Ownership [Domain]
Ownership [Domain]
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Total Shareholder Return [Text Block]
Fair Value Measurements, Recurring and Nonrecurring [Table]
Fair Value, Recurring and Nonrecurring [Table]
Depreciation
Depreciation, Depletion and Amortization
Other non-current assets
Other Assets, Noncurrent
Customer [Domain]
Customer [Domain]
Entity Central Index Key
Entity Central Index Key
Recovery of direct costs
Recovery of Direct Costs
PEO Name
PEO Name
Revenues
Revenues
Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year
Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]
Outstanding Aggregate Erroneous Compensation Amount
Outstanding Aggregate Erroneous Compensation Amount
OMERS
OMERS [Member]
OMERS
Comprehensive income (loss)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Contingent consideration
Fair value of contingent consideration
Liability at beginning of the period
Liability at end of the period
Business Combination, Contingent Consideration, Liability, Noncurrent
Arrangement Duration
Trading Arrangement Duration
Schedule of Segment Reporting Information, by Segment [Table]
Schedule of Segment Reporting Information, by Segment [Table]
Segments [Axis]
Segments [Axis]
Prepaid expenses and other assets
Increase (Decrease) in Prepaid Expense and Other Assets
Exercise Price
Award Exercise Price
Entity Filer Category
Entity Filer Category
Class of Stock [Domain]
Class of Stock [Domain]
Local Phone Number
Local Phone Number
Additional 402(v) Disclosure
Additional 402(v) Disclosure [Text Block]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Share price (in USD per share)
Share Price
Subsequent Event Type [Axis]
Subsequent Event Type [Axis]
Assets
Assets [Abstract]
Underlying Security Market Price Change
Underlying Security Market Price Change, Percent
Balance Sheet Location [Axis]
Statement of Financial Position Location, Balance [Axis]
Sale of future royalties
Liabilities Related To Sale Of Future Royalties [Text Block]
Liabilities Related To Sale Of Future Royalties
Fair value measurements
Fair Value Disclosures [Text Block]
Stockholders’ equity
Equity, Attributable to Parent [Abstract]
Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year
Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]
Award vesting rights, percentage
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage
Entity Address, Address Line One
Entity Address, Address Line One
Premium on closing stock price (as a percent)
Premium on Closing Stock Price
Premium on Closing Stock Price
Research and development
Research and Development Expense
Accumulated Other Comprehensive Loss
AOCI Attributable to Parent [Member]
Arbutus Inc.
Arbutus Inc. [Member]
Arbutus Inc. [Member]
Investment, Name [Axis]
Investment, Name [Axis]
Lease liability, non-current
Operating Lease, Liability, Noncurrent
Change in fair value of contingent consideration
Increase (Decrease) In Fair Value Of Contingent Consideration Liability
Increase (Decrease) In Fair Value Of Contingent Consideration Liability
Ownership [Axis]
Ownership [Axis]
Loss on impairment of leasehold improvements and lab equipment
Restructuring, Settlement and Impairment Provisions
Fair Value as of Grant Date
Award Grant Date Fair Value
Entity Registrant Name
Entity Registrant Name
Stock Price or TSR Estimation Method
Stock Price or TSR Estimation Method [Text Block]
Anti-dilutive common shares excluded from calculation of loss per common share (in shares)
Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements
Restricted stock units granted during period (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period
Bona fide collaboration Percentage
Bona fide collaboration Percentage
Bona fide collaboration Percentage
Purchase of investments in marketable securities
Payments to Acquire Investments
Related Party Transaction [Line Items]
Related Party Transaction [Line Items]
Document Quarterly Report
Document Quarterly Report
Registration Statement [Axis]
Registration Statement [Axis]
Registration Statement
Total
Assets, Fair Value Disclosure
Debt securities, available-for-sale, unrealized loss Position, number of positions
Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions
Changed Peer Group, Footnote
Changed Peer Group, Footnote [Text Block]
Counterparty Name [Domain]
Counterparty Name [Domain]
Genevant
Genevant Sciences Corporation [Member]
Genevant Sciences Corporation [Member]
Net accretion and amortization of investments in marketable securities
Accretion (Amortization) of Discounts and Premiums, Investments
Adjustment To PEO Compensation, Footnote
Adjustment To PEO Compensation, Footnote [Text Block]
Accrued investment income receivable
Accrued Investment Income Receivable
Cash Equivalents, Fair Value Disclosure
Cash Equivalents, Fair Value Disclosure
Cash Equivalents, Fair Value Disclosure
Schedule of accounts payable and accrued liabilities
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]
Related and Nonrelated Parties [Axis]
Related and Nonrelated Parties [Axis]
Grant date fair value (in USD per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Title
Trading Arrangement, Individual Title
Peer Group Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Consolidated net loss
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
Imdusiran IM-PROVE I, II & III clinical trials expense
Imdusiran IM-PROVE I, II & III Clinical Trials Expense
Imdusiran IM-PROVE I, II & III Clinical Trials Expense
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Restatement Determination Date:
Restatement Determination Date [Axis]
Non-PEO NEO
Non-PEO NEO [Member]
Issuance of common shares pursuant to ESPP
Stock Issued During Period, Value, Employee Stock Purchase Plan
Sale of Stock [Axis]
Sale of Stock [Axis]
Gross Unrealized Gain
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Name
Trading Arrangement, Individual Name
All Award Types
Award Type [Domain]
Equity Awards Adjustments
Equity Awards Adjustments [Member]
Pension Benefits Adjustments, Footnote
Pension Benefits Adjustments, Footnote [Text Block]
Compensation Amount
Outstanding Recovery Compensation Amount
Recovery of Erroneously Awarded Compensation Disclosure [Line Items]
Cumulative Collaboration Revenue Recognized
Contract with Customer, Liability, Revenue Recognized
Accrued lease-related operating expenses
Accrued Rent
MNPI Disclosure Timed for Compensation Value
MNPI Disclosure Timed for Compensation Value [Flag]
Name
Awards Close in Time to MNPI Disclosures, Individual Name
Restructuring Type [Axis]
Restructuring Type [Axis]
Change in fair value of contingent consideration
Increase (decrease) in fair value of contingent consideration
Change in fair value of liability
Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)
Aggregate Erroneous Compensation Not Yet Determined
Aggregate Erroneous Compensation Not Yet Determined [Text Block]
Deferred Revenue Arrangement, by Type [Table]
Deferred Revenue Arrangement, by Type [Table]
Revenue
Revenues [Abstract]
Enantigen's Selling Shareholders
Enantigen's Selling Shareholders [Member]
Enantigen's Selling Shareholders
Cash Equivalents, at Carrying Value
Cash Equivalents, at Carrying Value
Stock-based compensation expense
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Accumulated other comprehensive loss
Accumulated Other Comprehensive Income (Loss), Net of Tax
Financial Instruments [Domain]
Financial Instruments [Domain]
Unrealized loss on available-for-sale securities
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
Litigation Case [Axis]
Litigation Case [Axis]
Segments [Domain]
Segments [Domain]
Income Statement Location [Axis]
Statement of Income Location, Balance [Axis]
Investments in marketable securities
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]
Aggregate Pension Adjustments Service Cost
Aggregate Pension Adjustments Service Cost [Member]
Fair Value Hierarchy and NAV [Domain]
Fair Value Hierarchy and NAV [Domain]
Other deferred costs, gross
Other Deferred Costs, Gross
Balance Sheet Location [Domain]
Statement of Financial Position Location, Balance [Domain]
Minimum
Minimum [Member]
Non-cash interest expense
Non Cash Interest Expense Related To Sale Of Future Royalties
Non Cash Interest Expense Related To Sale Of Future Royalties
Amortization of other deferred charges
Amortization of Other Deferred Charges
Net loss attributable to common shareholders per share
Earnings Per Share, Policy [Policy Text Block]
Accumulated depreciation of property and equipment
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Company Selected Measure Name
Company Selected Measure Name
Other Liabilities Disclosure [Line Items]
Other Liabilities Disclosure [Line Items]
Other Liabilities Disclosure [Line Items]
Gross proceeds from sale of royalty interest. before advisory fees
Gross Proceeds From Royalty Interest Sold
Gross Proceeds From Royalty Interest Sold
Aggregate Available
Trading Arrangement, Securities Aggregate Available Amount
Long Term Marketable Securities
Investments in marketable securities, noncurrent [Member]
Investments in marketable securities, noncurrent
Jefferies LLC
Jefferies LLC [Member]
Jefferies LLC
Issuance of common shares pursuant to ESPP
Proceeds from Stock Plans
Stock Appreciation Rights (SARs)
Stock Appreciation Rights (SARs) [Member]
All Executive Categories
All Executive Categories [Member]
Stockholders' Equity Note [Abstract]
Issued and outstanding: 191,641,511 (December 31, 2024: 189,963,492)
Common Stock, Value, Issued
Restructuring Plan [Domain]
Restructuring Plan [Domain]
Contingencies and commitments
Commitments and Contingencies Disclosure [Text Block]
Diluted (in shares)
Weighted Average Number of Shares Outstanding, Diluted
Non-GAAP Measure Description
Non-GAAP Measure Description [Text Block]
Business Combination [Axis]
Business Combination [Axis]
Entity Small Business
Entity Small Business
Costs related to collaboration
Other Cost and Expense, Operating
Potential milestone payments
Potential Milestone Payments
Represents the potential milestone payments amount.
Document Transition Report
Document Transition Report
Ownership interest in equity method investment (as a percentage)
Equity Method Investment, Ownership Percentage
Underlying Securities
Award Underlying Securities Amount
Number of wholly-owed subsidiaries
Wholly Owned Subsidiaries Included in Financial Statements
Represents the number of wholly owned subsidiaries included in the reporting of the financial statements.
Equity Component [Domain]
Equity Component [Domain]
Document Period End Date
Document Period End Date
PEO Actually Paid Compensation Amount
PEO Actually Paid Compensation Amount
Development and regulatory milestones payment per licensed compound series, maximum
License Agreement Maximum Development And Regulatory Milestone Payments Per License
License Agreement, Maximum Development and Regulatory Milestone Payments Per License
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Awards Close in Time to MNPI Disclosures, Table
Awards Close in Time to MNPI Disclosures [Table Text Block]
Royalty guarantees commitments percentage
Royalty Guarantees Commitments Percentage
Represents the royalty guarantees commitments percentage.
Revenue from Contract with Customer [Abstract]
Document Type
Document Type
Level 3
Fair Value, Inputs, Level 3 [Member]
Name
Outstanding Recovery, Individual Name
Marketable Securities [Table]
Marketable Securities [Table]
Gain Contingencies [Table]
Loss Contingencies [Table]
Additional paid-in capital
Additional Paid in Capital
Product and Service [Axis]
Product and Service [Axis]
Issuance of common shares pursuant to the Open Market Sale Agreement
Proceeds from issuance of shares under the agreement
Proceeds from Issuance of Common Stock
Litigation Status [Domain]
Litigation Status [Domain]
All Individuals
All Individuals [Member]
Fair Value Disclosures [Abstract]
Acquisition of property and equipment
Payments to Acquire Property, Plant, and Equipment
Name
Forgone Recovery, Individual Name
Total current assets
Assets, Current
Range [Axis]
Statistical Measurement [Axis]
Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested
Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]
Other Liabilities Disclosure [Abstract]
Weighted average number of common shares
Weighted Average Number Of Common Shares [Abstract]
Weighted average number of common shares
Non-cash royalty revenue
Non-cash royalty revenue
Non Cash Royalty Revenue Related To Sale Of Future Royalties
Non Cash Royalty Revenue Related To Sale Of Future Royalties
Non Cash Royalty Revenue Related To Sale Of Future Royalties
Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Amount
Peer Group Issuers, Footnote
Peer Group Issuers, Footnote [Text Block]
Erroneous Compensation Analysis
Erroneous Compensation Analysis [Text Block]
Current liabilities:
Liabilities, Current [Abstract]
Total operating expenses
Operating Expenses
Rule 10b5-1 Arrangement Terminated
Rule 10b5-1 Arrangement Terminated [Flag]
Level 1
Fair Value, Inputs, Level 1 [Member]
Foreign exchange gain (loss)
Gain (Loss), Foreign Currency Transaction, before Tax
Deferred license revenue, current
Deferred Revenue, Current
Schedule of Related Party Transactions, by Related Party [Table]
Related Party Transaction [Table]
Diluted (in USD per share)
Earnings Per Share, Diluted
Erroneously Awarded Compensation Recovery
Erroneously Awarded Compensation Recovery [Table]
Accounts receivable
Accounts Receivable, after Allowance for Credit Loss, Current
Title of 12(b) Security
Title of 12(b) Security
Arbutus Plans
Arbutus Plans [Member]
Arbutus Plans [Member]
Labor hours
Service, Other [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Number of shares issued under agreement (in sales)
Sale of Stock, Number of Shares Issued in Transaction
Net income (loss) per common share
Earnings Per Share [Abstract]
Restructuring Plan [Axis]
Restructuring Plan [Axis]
Total other income
Nonoperating Income (Expense)
Investments, Debt and Equity Securities [Abstract]
Investment in Genevant
Equity Method Investments and Joint Ventures Disclosure [Text Block]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Investments in marketable short-term securities
Debt Securities, Available-for-Sale, Current
Accounts payable and accrued liabilities
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
Research and development employee expense, lab supplies and overhead
Research and development employee expense, lab supplies and overhead
Research and development employee expense, lab supplies and overhead
Money Market Funds, at Carrying Value
Money Market Funds, at Carrying Value
Award Timing Disclosures [Line Items]
Non-cash interest expense
Liability From Sale Of Future Royalties, Non Cash Interest Expense
Liability From Sale Of Future Royalties, Non Cash Interest Expense
Entitlement of royalties to be received
Royalty Interest Sold, Maximum Royalties For Buyer
Royalty Interest Sold, Maximum Royalties For Buyer
Weighted average exercise price (in USD per share)
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Fair Value, Measurement Frequency [Domain]
Measurement Frequency [Domain]
Other early research and development programs expense
Other Research and Development Expense
Shareholders’ equity
Equity [Text Block]
Deferred Revenue Arrangement [Line Items]
Deferred Revenue Arrangement [Line Items]
Acuitas Therapeutics, Inc.
Acuitas Therapeutics Inc. [Member]
Acuitas Therapeutics Inc.
Net income (loss)
Net loss
Net Income (Loss)
Net Income (Loss) Attributable to Parent
Expiration Date
Trading Arrangement Expiration Date
Pending Litigation
Pending Litigation [Member]
Restructuring
Restructuring, Impairment, and Other Activities Disclosure [Text Block]
Other liabilities
Increase (Decrease) in Other Operating Liabilities
Property and equipment, net of accumulated depreciation and impairment of $13,315 (December 31, 2024: $12,996)
Property, Plant and Equipment, Net
Segment Reporting Information [Line Items]
Segment Reporting Information [Line Items]
Preferred stock, shares authorized (in shares)
Preferred Stock, Shares Authorized
Restructuring costs
Restructuring Charges
Adoption Date
Trading Arrangement Adoption Date
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Net Income [Text Block]
Accounts receivable
Increase (Decrease) in Accounts Receivable
Schedule of Restructuring and Related Costs [Table]
Restructuring Cost [Table]
Entity Current Reporting Status
Entity Current Reporting Status
Customer [Axis]
Customer [Axis]
Awards Close in Time to MNPI Disclosures
Awards Close in Time to MNPI Disclosures [Table]
Revenue from External Customers by Products and Services [Table]
Segment Reporting, Revenue from External Customer, Product and Service [Table]
Gain (loss) from operations
Operating Income (Loss)
Transaction costs on sale of royalties
Transaction Costs Related To Sale Of Future Royalties
Transaction Costs Related To Sale Of Future Royalties
Deficit
Retained Earnings (Accumulated Deficit)
Financial Instrument [Axis]
Financial Instrument [Axis]
Non-cash items:
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Noncash Item [Abstract]
Statement of Financial Position [Abstract]
Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested
Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]
Executive Category:
Executive Category [Axis]
Class of Stock [Axis]
Class of Stock [Axis]
Current Fiscal Year End Date
Current Fiscal Year End Date
Subsequent Event Type [Domain]
Subsequent Event Type [Domain]
Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]
Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]
Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]
Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table
Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]
Contingencies and Commitments [Line Items]
Contingencies and Commitments [Line Items]
Payables and Accruals [Abstract]
Statement [Table]
Statement [Table]
Impairment of leasehold improvements
Impairment of Leasehold
Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]
Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]
Collaborations, contracts and licensing agreements
Collaborative Arrangement Disclosure [Text Block]
FINANCING ACTIVITIES
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]
Equity Awards Adjustments, Excluding Value Reported in Compensation Table
Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]
Qilu Pharmaceutical Co, LTD.
Qilu Pharmaceutical Co, LTD. [Member]
Qilu Pharmaceutical Co, LTD.
Total deferred license revenue
Contract with Customer, Liability
Assets and liabilities measured at fair value on a recurring basis
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents [Abstract]
Anti-dilutive common shares excluded from calculation of loss per common share (in shares)
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
All Adjustments to Compensation
All Adjustments to Compensation [Member]
Accounts payable and accrued liabilities
Accounts payable and accrued liabilities
Accounts Payable and Accrued Liabilities, Current
Amendment Flag
Amendment Flag
Termination Date
Trading Arrangement Termination Date
Net cash provided by financing activities
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Adopted [Flag]
Measure:
Measure [Axis]
Schedule of activity related to the net liability from inception of the Agreement
Liabilities Related To Sale Of Future Royalties Roll Forward [Table Text Block]
Liabilities Related To Sale Of Future Royalties Roll Forward
Issuance of common shares upon vesting of RSUs
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures
Basic (in shares)
Weighted Average Number of Shares Outstanding, Basic
US corporate bonds
US Corporate Bonds [Member]
US Corporate Bonds
Schedule of basic and diluted net income (loss) per common share
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Director
Director [Member]
Related Party Transaction [Domain]
Related Party Transaction [Domain]
Segment Reporting [Abstract]
Pay vs Performance Disclosure, Table
Pay vs Performance [Table Text Block]
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Entity Tax Identification Number
Entity Tax Identification Number
Royalty interest, % interest
Royalty interest, Percent interest
Royalty interest, % interest
Trade accounts payable
Accounts Payable, Trade, Current
Restructuring and Related Activities [Abstract]
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Expense of Enforcement, Amount
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common shares, shares issued (in shares)
Common Stock, Shares, Issued
Options granted during period (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Unrealized (loss) gain on available-for-sale securities
Debt Securities, Available-for-Sale, Unrealized Gain (Loss)
Interest expense
Interest Expense, Nonoperating
Trading Arrangement:
Trading Arrangement [Axis]
Total Shareholder Return Amount
Total Shareholder Return Amount
Registration Statement [Domain]
Registration Statement [Domain]
Registration Statement [Domain]
Gain Contingencies [Line Items]
Loss Contingencies [Line Items]
Insider Trading Arrangements [Line Items]
Security Exchange Name
Security Exchange Name
Liability Related To Sale Of Future Royalties [Roll Forward]
Liability Related To Sale Of Future Royalties [Roll Forward]
Liability Related To Sale Of Future Royalties [Roll Forward]
Total liabilities
Liabilities
Antidilutive Securities, Name [Domain]
Antidilutive Securities, Name [Domain]
Pension Adjustments Prior Service Cost
Pension Adjustments Prior Service Cost [Member]
Operating expenses
Operating Expenses [Abstract]
Material Terms of Trading Arrangement
Material Terms of Trading Arrangement [Text Block]
Modification of Equity Awards
Modification of Equity Awards [Member]
Modification of Equity Awards
Statement [Line Items]
Statement [Line Items]
Rule 10b5-1 Arrangement Adopted
Rule 10b5-1 Arrangement Adopted [Flag]
Cash and cash equivalents
Cash and Cash Equivalent
Counterparty Name [Axis]
Counterparty Name [Axis]
Consulting Services
Consulting Services [Member]
Consulting Services
Common Shares
Common Stock [Member]
Fair Value
Debt Securities, Available-for-Sale
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Non-NEOs
Non-NEOs [Member]
Increase in cash and cash equivalents
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Arbutus Biopharma Corp
Arbutus Biopharma Corp [Member]
Arbutus Biopharma Corp
Professional fee accruals
Accrued Professional Fees, Current